References
  1. Xiang H, Xue Y, Chen Z, et al. The association between left ventricular hypertrophy and the occurrence and prognosis of atrial fibrillation: A meta-analysis. Front Cardiovasc Med 2021;8: 639993. doi: 10.3389/fcvm.2021.639993
  2. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk of sudden death. J Am Coll Cardiol 1998;32(5): 1454-1459.
  3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006;48: 854-906.
  4. Aronson RS. Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol 1991;2: 249-261.
  5. Ben-David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 1992;20: 1576-1584.
  6. Yan GX, Rials SJ, Wu Y, Liu T, Xu X, Marinchak RA, Kowey PR. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol Heart Circ Physiol 2001;281: H1968-H1975.
  7. Gillis AM, Mathison HJ, Kulisz E, Lester WM. Dispersion of ventricular repolarization in left ventricular hypertrophy: influence of afterload and dofetilide. J Cardiovasc Electrophysiol 1998;9(9): 988-997.
  8. Kowey PR, Friehling TD, Sewter J, Wu Y, Sokil A, Paul J, Nocella J. Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation 1991;83: 2067-2075.
  9. Wann DG, Medoff BS, Mehdi NA, et al. Dofetilide use is not associated with increased mortality in patients with left ventricular hypertrophy and atrial fibrillation. J Cardiovasc Electrophysiol 2022; In Press. (This volume of JCE)
  10. Abraham JM, Saliba WI, Vekstein C, et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 2015;8: 772-776.
  11. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019;140(2): e125-e151.
  12. Chung R, Houghtaling PL, Tchou M, Niebauer MJ, Lindsay BD, Tchou PJ, Chung MK. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: Impact on mortality. Pacing Clin Electrophysiol 2014;37(10):1338-1348.
  13. Barbieri A, Albini A, Maisano A, et al. Clinical value of complex echocardiographic left ventricular hypertrophy classification based on concentricity, mass, and volume quantification. Front Cardiovasc Med 2021;https://doi.org/10.3389/fcvm.2021.667984
  14. Nadarajah R, Patel PA, Tayebjee MH. Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans? J Human Hypertension 2021;35: 492-498.
  15. Moore JC, Trager L, Anzia L, et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. Pacing Clin Electrophysiol 2018;41: 396-401.
  16. Hohnloser SH, Crijns, HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360: 668-678.
  17. Reiffel JA, Naccarelli GV. Antiarrhythmic drug therapy for atrial fibrillation. Are the guidelines guiding clinical practice? Clin Cardiol 2006; 29: 97-102.
  18. Naccarelli GV. Antiarrhythmic drugs for atrial fibrillation in the real world. J Am Coll Cardiol EP 2019:5(2): 242-243.
  19. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish-investigations of arrhythmia and mortality on dofetilide (Diamond) substudy. Circulation. 2001 Jul 17;104(3): 292-296.
  20. Shantha G, Chugh A, Crawford T, et al. Comparative efficacy of dofetilide versus amiodarone in patients with atrial fibrillation. J Am Coll Cardiol: EP 2021;7: 642-648.